[A22-108] Relugolix (prostate cancer) – Benefit assessment acc. to § 35a Social Code Book V
Last updated 06.04.2023
Project no.:
A22-108
Commission:
Commission awarded on 17.10.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Patients with hormone-sensitive prostate cancer
- Patients with advanced hormone-sensitive prostate cancer who are candidates for local therapy: added benefit not proven
- Patients with advanced hormone-sensitive prostate cancer who are not candidates for local therapy: added benefit not proven
- Patients with advanced hormone-sensitive prostate cancer and with PSA recurrence or clinical recurrence after primary local therapy: added benefit not proven
- Patients with metastatic hormone-sensitive prostate cancer who are candidates for combination therapy: added benefit not proven
- Patients with metastatic hormone-sensitive prostate cancer who are not candidates for combination therapy: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2023-01-16.
| Project no. | Title | Status |
|---|---|---|
| A23-13 | Relugolix (prostate cancer) – Addendum to Commission A22-108 | Commission completed |
Federal Joint Committee (G-BA)
2023-04-06 A G-BA decision was published.